Oruka Therapeutics, Inc. (ORKA) Stock
4 of the hedge funds AlphaScala tracks reported ORKA in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Viking Global Investors's at $143.09M. Company insiders reported 0 open-market buys and 60 sales on SEC Form 4 in the 90 days to Nov 6, 2026.
Which hedge funds own ORKA?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Viking Global Investors Andreas Halvorsen | 1.50M | $143.09M | -44% |
| Citadel Ken Griffin | 1.12M | $106.50M | +11% |
| Blackstone | 237K | $22.57M | NEW |
| Millennium Management Israel Englander | 33K | $3.13M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Oruka Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 2, 26 | Klein Lawrence Otto | Chief Executive Officer | SELL | 6.5K | $613K |
| Nov 2, 26 | Klein Lawrence Otto | Chief Executive Officer | SELL | 15.0K | $1.4M |
| Nov 2, 26 | Klein Lawrence Otto | Chief Executive Officer | SELL | 2.4K | $236K |
| Nov 2, 26 | Klein Lawrence Otto | Chief Executive Officer | SELL | 756 | $74K |
| Nov 2, 26 | Klein Lawrence Otto | Chief Executive Officer | SELL | 300 | $30K |
| Oct 20, 26 | Quinlan Paul T | General Counsel | SELL | 400 | $30K |
| Oct 20, 26 | Quinlan Paul T | General Counsel | SELL | 500 | $38K |
| Oct 20, 26 | Quinlan Paul T | General Counsel | SELL | 1.0K | $77K |
| Oct 20, 26 | Quinlan Paul T | General Counsel | SELL | 4.1K | $323K |
| Oct 20, 26 | Quinlan Paul T | General Counsel | SELL | 3.0K | $238K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →ORKA price chart
Powered by TradingViewWhat does Oruka Therapeutics, Inc. do?
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications. Its lead product, ORKA-001, targets the p19 subunit of interleukin-23 and is in Phase 2 trials for moderate-to-severe psoriasis, featuring half-life extension technology that supports potential once-per-year dosing. The co-lead program, ORKA-002, targets interleukin-17A and interleukin-17F for psoriasis, psoriatic arthritis, and conditions like hidradenitis suppurativa, with Phase 1 data indicating a half-life of 75-80 days to enable twice-yearly or quarterly dosing. The company also advances ORKA-003 targeting an undisclosed pathway. These biologics aim to provide high-affinity binding, extended exposure, and reduced dosing frequency to improve patient outcomes in chronic skin and autoimmune diseases. Founded in 2004 and headquartered in Menlo Park, California, Oruka Therapeutics operates in the biotechnology sector, focusing on dermatology and immunology pipelines to address unmet needs in the inflammatory disease market.